Loading patent…
AssigneeThe Curators of the University of Missouri
InventorsTimothy J. Hoffman, Wynn A. Volkert, Gary Sieckman, Charles J. Smith, Hariprasad Gali
Estimating the term…
A compound for use as a therapeutic or diagnostic radiopharmaceutical includes a group capable of complexing a medically useful metal attached to a moiety which is capable of binding to a gastrin releasing peptide receptor. A method for treating a subject having a neoplastic disease includes administering to the subject an effective amount of a radiopharmaceutical having a metal chelated with a chelating group attached to a-moiety capable of binding to a gastrin releasing peptide receptor expressed on tumor cells with subsequent internalization inside of the cell. A method of forming a therapeutic or diagnostic compound includes reacting a metal synthon with a chelating group covalently linked with a moiety capable of binding a gastrin releasing peptide receptor.
A compound comprising a metal complexed with a chelating group attached to a gastrin releasing peptide (GRP) receptor agonist which includes a bombesin agonist binding moiety.
A complex comprising a metal and a compound having a structure of the formula X-Y-B wherein X is a metal chelating group, Y is a spacer group or covalent bond and B is a gastrin releasing peptide receptor agonist which includes a bombesin agonist binding moiety.
A method of treating patient using radioisotope therapy by administering an effective amount of a pharmaceutical comprising a metal complex with a chelating group with a gastrin releasing peptide receptor agonist which includes a bombesin agonist moiety.
A method of forming a therapeutic or diagnostic compound comprising the step of reacting a metal complexed with a chelating group with a gastrin releasing peptide receptor agonist which includes a bombesin agonist moiety.
Dependencies are inferred from the claim text.